Prothena Corp. Plc

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 5.62%219.950.0%$1926.77m
BIIBBiogen, Inc. -1.69%374.471.7%$1312.42m
SNSSSunesis Pharmaceuticals, Inc. -7.41%11.870.7%$829.76m
NVAXNovavax, Inc. 6.53%192.8079.8%$799.62m
AMGNAmgen, Inc. -0.13%239.921.3%$662.58m
BNTXBioNTech SE 3.42%233.820.0%$571.85m
VRTXVertex Pharmaceuticals, Inc. 0.48%188.601.9%$536.66m
GILDGilead Sciences, Inc. -0.42%67.071.0%$495.93m
REGNRegeneron Pharmaceuticals, Inc. 0.08%534.672.7%$388.70m
ILMNIllumina, Inc. 0.69%464.253.5%$351.79m
ALXNAlexion Pharmaceuticals, Inc. -0.56%179.652.0%$338.01m
OCGNOcugen, Inc. -5.68%6.980.0%$323.22m
TXG10X Genomics, Inc. 0.28%198.430.0%$177.84m
EXASEXACT Sciences Corp. 0.65%128.4918.1%$177.55m
TECHBio-Techne Corp. 0.16%440.934.5%$164.11m

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.